Embecta (NASDAQ:EMBC) Shares Up 4.5% – Time to Buy?

Embecta Corp. (NASDAQ:EMBC) shares shot up 4.5% on Thursday . The company traded as high as $9.35 and last traded at $9.2610. 115,297 shares changed hands during trading, a decline of 85% from the average session volume of 780,064 shares. The stock had previously closed at $8.86.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on EMBC. BTIG Research reissued a “buy” rating and issued a $25.00 price objective on shares of Embecta in a report on Friday, February 6th. Wall Street Zen raised Embecta from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 7th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Embecta in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, Embecta has a consensus rating of “Hold” and an average price target of $18.50.

Embecta Stock Down 2.5%

The firm has a market cap of $526.47 million, a price-to-earnings ratio of 3.75 and a beta of 1.10. The stock’s 50 day moving average is $10.45 and its 200 day moving average is $12.39.

Embecta (NASDAQ:EMBC) last released its earnings results on Thursday, February 5th. The company reported $0.71 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.04. The firm had revenue of $261.20 million during the quarter, compared to the consensus estimate of $258.07 million. Embecta had a negative return on equity of 26.66% and a net margin of 12.92%.The firm’s revenue for the quarter was down .3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.65 earnings per share. Embecta has set its FY 2026 guidance at 2.800-3.00 EPS. Analysts anticipate that Embecta Corp. will post 2.85 earnings per share for the current fiscal year.

Embecta Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 17th. Stockholders of record on Friday, February 27th were issued a $0.15 dividend. The ex-dividend date was Friday, February 27th. This represents a $0.60 annualized dividend and a dividend yield of 6.7%. Embecta’s dividend payout ratio is 25.32%.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of EMBC. Rockefeller Capital Management L.P. lifted its holdings in Embecta by 25.0% in the 4th quarter. Rockefeller Capital Management L.P. now owns 344,544 shares of the company’s stock valued at $4,093,000 after acquiring an additional 68,925 shares during the last quarter. Alpine Global Management LLC acquired a new position in shares of Embecta in the 4th quarter worth approximately $178,000. River Road Asset Management LLC raised its holdings in shares of Embecta by 5.3% in the 4th quarter. River Road Asset Management LLC now owns 3,416,401 shares of the company’s stock worth $40,587,000 after purchasing an additional 171,194 shares in the last quarter. Pacer Advisors Inc. raised its holdings in shares of Embecta by 49.3% in the 4th quarter. Pacer Advisors Inc. now owns 16,526 shares of the company’s stock worth $196,000 after purchasing an additional 5,460 shares in the last quarter. Finally, State of Tennessee Department of Treasury lifted its stake in Embecta by 23.9% during the fourth quarter. State of Tennessee Department of Treasury now owns 53,290 shares of the company’s stock valued at $633,000 after purchasing an additional 10,263 shares during the last quarter. 93.83% of the stock is owned by institutional investors and hedge funds.

Embecta Company Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.